Compugen Reports Q4 Revenue of $67.3 Million, a Significant Increase from Last Year

Compugen Ltd. (CGEN) reported Q4 revenue of $67.3 million, a significant increase from $1.5 million in the prior year. The company's CEO, Eran Ophir, attributed the growth to progress made in 2025 and the extension of its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca. Compugen also announced the appointment of Michele Holcomb as an independent director, bringing over 30 years of experience in biotechnology and healthcare.